Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for letting me know....this is history....
Thanks Renee. I appreciate the advice.
Potomac: CHKT will open on the Grey Sheets after the ten day suspension. Although it is not cast in stone it has been my observations that the best time to get out of a suspended stock is within the first trading days on the Grey Sheets. It becomes increasingly difficult to liquidate a position the longer a stock languishes on the Grey Sheets.
IMO.
From your experience,do you think there's any chance that they could correct the problem or should I write this one off?
CHKT SEC Suspension:
http://www.sec.gov/litigation/suspensions/2012/34-66418.pdf
SEC Admin Proceeding:
http://www.sec.gov/litigation/admin/2012/34-66419.pdf
This is a old PR I think from 2008 before the IP was acquired by British Biotech Corp in 2009.
Chemokine Therapeutics Announces outcomes From CTCE-0214 medical Trials system
January 19th, 2011 | by admin |
http://healthvv.com/2011/01/19/chemokine-therapeutics-announces-outcomes-from-ctce-0214-medical-trials-system/
Chemokine Therapeutics
Corp. (the “40?) (TSX:CTI, OTCBB:CHKT), a biotechnology firm
developing chemokine-based therapies to deal with cancer, blood issues, and
vascular conditions, is happy to announce outcomes of medical trials of its
hematological drug candidate, CTCE-0214.
The firm has accomplished the initially two levels with the 3 element phase
Ib medical trials for CTCE-0214. A complete of 57 regular nutritious volunteers
were evaluated by using numerous doses and evaluating intravenous versus
subcutaneous routes of administration. The research demonstrated CTCE-0214 to
be protected and nicely tolerated when administered intravenously as being a single or
after several doses had been administered on the day-to-day foundation for 5
consecutive days. There had been no really serious adverse occasions noted. topics
receiving subcutaneous administrations of CTCE-0214 did even so encounter
transient injection internet site reactions and nearby ache soon after single and repeated
administration with the drug. As demonstrated in an previously research,
administration of CTCE-0214 subcutaneously resulted within a 300% enhance in
neutrophil counts that peaked at around 12 hrs and had been sustained
above the baseline worth for around 48 hrs soon after every
administration. Administration by using the intravenous route demonstrated a
modest pharmacological neutrophil response to every dose administered soon after
each consecutive day of administration that has a obvious enhance in stem
cell numbers at three days by using colony forming assay strategies.
“209 encouraged by the outcomes of those medical research that will
serve as being a basis for long run improvement of CTCE-0214?, mentioned Dr. Hassan
Salari, President and CEO of Chemokine Therapeutics. “The 3rd element with the
phase Ib trial must supply us with further facts around the
benefits of combining CTCE-0214 with G-CSF.”
The major goal with the lately accomplished phase Ib research
conducted underneath a US-IND was to assess the security of CTCE-0214 in regular
health volunteers also as to assess the results of intravenous versus
subcutaneous administration. The unique protocol was amended to consist of a
subcutaneous cohort of topics for comparison on the planned intravenous
route of administration. These trials are made to check principally the
safety and optimum route of administration of CTCE-0214 in planning for
future medical trials that may assess the mobilization and regeneration
of infection-fighting white blood cells as well as other cells of hematopoietic
(blood) origin within a individual setting.
CTCE-0214 has the possible to revive a cancer individual’s immune process
and blood cells involving cycles of chemotherapy. within this medical situation,
patients may well be capable to acquire aggressive chemotherapy devoid of delay by
restoring infection-fighting white blood cells and rising platelet
counts to defend individuals from bleeding, and/or enhance in blood stem
cells appropriate for transplant.
About CTCE-0214
CTCE-0214 is often a steady peptide agonist of stromal cell-derived factor-1
(SDF-1), a important signaling molecule while in the proliferation, homing, engraftment
and growth of hematopoietic stem cells and white blood cells. SDF-1 is
also thought to get the job done as being a visitors controller for infection-fighting white
blood cells and progenitor cell migration supplying an important operate
to fight immunosuppression. CTCE-0214, primarily based on Chemokine’s preclinical
research, mimics the exercise with the healthy chemokine SDF-1 by rising
the stage of white blood cells (neutrophils), bleeding prevention cells
(platelets) and stem cells (primitive blood forming cells) while in the blood.
These findings happen to be confirmed by way of impartial laboratories at
Memorial Sloan Kettering Cancer middle and Cornell health-related college in New
York along with the Walther Cancer Institute in Indianapolis.
About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
Chemokine Therapeutics is often a product-focused biotechnology firm
developing prescription drugs while in the discipline of chemokines. Chemokines really are a class of
signaling proteins which play a vital part while in the development,
differentiation, and maturation of cells essential for fighting infection
as nicely as tissue restore and regeneration. Chemokines also have an
important part in cancer metastasis and development. Chemokine Therapeutics is often a
leader in analysis while in the discipline of chemokines and has many items in
various levels of improvement.
Safe Harbor assertion underneath the U. S. personal Securities Litigation
Reform Act of 1995: Statements within this document about managements’
future expectations, beliefs, targets, options or prospects constitute
forward-looking statements that entail dangers and uncertainties, which may possibly
cause real outcomes to differ materially through the statements created. For
this goal, any statements which have been contained herein that will not be
statements of historical reality may possibly be deemed to become forward-looking
statements. devoid of limiting the foregoing, the words “believes”,
“anticipates”, “132?, “intends”, “will”, “170?, “expects”, “144?,
and comparable expressions are meant to recognize forward-looking
statements. you’re cautioned that these kinds of statements are topic to a
multitude of dangers and uncertainties that may induce real outcomes,
future situations, or occasions to differ materially from individuals projected
in the forward-looking statements. These dangers consist of, but will not be constrained
to, individuals linked with all the accomplishment of analysis and improvement applications,
the regulatory approval method, competitors, securing and preserving
corporate alliances, market place acceptance with the firm’s items, the
availability of federal government and insurance coverage reimbursements for that firm’s
products, the power of intellectual house, financing ability, the
potential dilutive results of any financing, reliance on subcontractors and
key personnel as well as other dangers thorough from time-to-time while in the firm’s
public disclosure paperwork as well as other filings with all the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are created as with the date hereof, along with the firm
disclaims any intention and has no obligation or duty, besides as
required by legislation, to update or revise any forward-looking statements,
whether as being a outcome of new facts, long run occasions, or otherwise.
Chemokine Therapeutics Corp
http://www.chemokine.net/
Post a Comment
Name (required)
E-mail (will not be published) (required)
Website
Tags
Alcohol Alzheimer and As at Be blood Brain breast by Can cancer Care Cells Children Clinical Disease Drug FDA for From Health Heart Help in Is May more new of on Patients Phase Research Researchers risk study That the to Treatment UK Use With women
Categories
Abortion
Acid Reflux / GERD
ADHD
Aid / Disasters
Alcohol / Addiction / Illegal Drugs
Allergy
Alzheimer's / Dementia
Anxiety / Stress
Arthritis / Rheumatology
Asbestos / Mesothelioma
Autism News
Back Pain
Bio-terrorism / Terrorism
Biology / Biochemistry
Bipolar
Bird Flu / Avian Flu
Blood / Hematology
Body Aches
Bones / Orthopedics
Breast Cancer
Cancer / Oncology
Cardiovascular / Cardiology
Caregivers / Homecare
Medical Health News
Sponsored Links
Tag cloud
blood Alzheimer Help Research Use Children Health in With That of Heart Researchers the on Can risk Disease Care Be by Is at May for Cells Patients more women new breast Brain Alcohol FDA cancer From Phase and study Treatment to As Clinical Drug UK
Recent Posts
DA feedback On circumstance Kansas AG Kline Cited For Necessity Of Investigations Into Late-Term Abortions, little one intercourse Crimes
Kaiser every day females’s well being coverage Report Highlights challenges connected To 2006 Election
Kaiser day by day girls’s wellness coverage Report Highlights troubles connected To 2006 Elections
NARAL Pro-Choice America Files short In situation demanding New Hampshire Parental Notification Law
Wyo. Gubernatorial Candidate Hunkins Will look for Abortion Ban If Roe Overturned, Mandate 25-Year Sentences For Assaults On Pregnant lady
Archives
March 2011
February 2011
January 2011
December 2010
January 1970
Blogroll
Documentation
Plugins
Suggest Ideas
Support Forum
Themes
WordPress Blog
WordPress Planet
Institutional Buying:
Name Ownership Trend
Previous 8 Qtrs Shares Change % Total
Shares Held % Total
Assets Date
Garrison Bradford & Associates Inc Premium 30,000 0 0 0 12/31/2010
Total: Top 1 Top Institutions Premium 30,000 0 0
CHKT CEO, Mr Walter Korz is also on the board of directors for Wex Pharmaceuticals and the major shareholder there is Pharmagesic:
Pharmagesic Announces Take Up of Additional Shares of WEX Pharmaceuticals Inc.
02/28/2011
Montreal, Canada (February 28, 2011) – Pharmagesic (Holdings) Inc. (“Pharmagesic”) announced today that pursuant to the offer by its wholly-owned subsidiary, 7735308 Canada Limited (the “Offeror” and, together with Pharmagesic, the “Offering Parties”) to acquire all of the outstanding restricted voting shares (the “WEX Shares”) of WEX Pharmaceuticals Inc. (“WEX”) not already owned by Pharmagesic for C$0.14 cash per WEX Share (the “Offer”) it has taken up an additional 54,590 WEX Shares, which, when added to the WEX Shares previously held, amount to a total of 398,496,186 WEX Shares, representing over 90% of the WEX Shares outstanding. It is the current intention of the Offering Parties to enter into a subsequent acquisition transaction to acquire all of the remaining WEX Shares that are not acquired pursuant to the Offer, which is open until 5:00 p.m. (Vancouver time) on March 10, 2011.
WEX shareholders who have already deposited their WEX Shares to the Offer do not need to take any further action to accept the Offer. Shareholders who have not yet deposited their WEX Shares in acceptance of the Offer may tender their WEX Shares to the Offer at any time prior to 5:00 p.m. (Vancouver time) on March 10, 2011.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. WEX’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market.
About Pharmagesic (Holdings) Inc.
Pharmagesic (Holdings) Inc. is an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”). CKLS is a company listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). Bearing the mission of improving the quality of life, CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water business as well as investment in various financial and investment products. Products developed by CKLS are categorized into the areas of human health and environmental sustainability. CKLS is a member of the Cheung Kong Group. For additional information, please visit www.ck-lifesciences.com.
British Canadian BioSciences Corp. Acquires Chemokine Therapeutics
Corp. Technology
http://www.bcbcorp.net/BCBC_PR_Technology_Aquisition_(11Jan10)[1].pdf
But from the looks of things BCBP acquired the whole company.
British Canadian Bioscience corp (a private BC biotechnology company) and CHKT has the same CEO and Science directors, Mr Korz and Mr Wong and also the same IP of CHKT is on the BSBP website, the 28 issued and 9 pending patents for:
1. Therapeutics for chemokine mediated diseases
2. CXCR4 antagonist treatment of hematopoeitic cells
3. Bicyclic aromatic chemokine receptor ligands
4. Therapeutic chemokine receptor antagonists
5. Cyclic peptides for modulating growth of neovessels and their use in therapeutics angiogenesis
6. Novel chemokine mimetics synthesis and their use
7. DNA encoding for recombinant polypeptide mutants of human SDF-1
Link to
http://www.bcbcorp.net/IntellectualProperty.html
Product Pipeline;
1.CTCE-9908 (Anti-Metastasis and Anti-Cancer)
2. CTCE-0214 (Hematological Support; mobilization of stem cells and neutrophils into the circulation)
3.CTCE-0324 (Peripheral Vascular Disease)
I think this is whats up:
VANCOUVER, Jan. 9 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp.
(the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing
chemokine-based therapies to treat cancer, blood disorders, and vascular
diseases, is pleased to announce that Chemokine Therapeutics (B.C.) Corp.
("CTBCC"), a wholly-owned subsidiary of Chemokine Therapeutics Corp. and
Globe Laboratories Inc. ("Globe"), have entered into a definitive agreement
wherein Globe agreed to sell certain assets (consisting mainly of
laboratory equipment and leasehold improvements) to CTBCC for consideration
of CD$375,935 based on the fair market value of these assets as determined
by an independent appraisal, and to cease all future research and
development services by Globe to the Company.
The acquisition of the assets and the termination of the development
agreement with Globe were initiated by the Company because management
believes that it is in the best interests of the Company to concentrate its
research and development in-house through its wholly-owned subsidiary,
CTBCC.
The Company, under a development agreement dated January 1, 2003 had
engaged Globe to carry out the Company's chemokine-based research work on a
contracted operating cost basis plus a 2% margin. Globe is controlled by
Dr. Hassan Salari and his family. Dr. Salari is also the Company's
President and Chief Executive Officer. Pursuant to this development
agreement between the Company and Globe, all proprietary interest,
including all patent rights, trademarks, copyright, trade secrets, and
confidential information of the research conducted by Globe on our products
is the exclusive property of the Company.
The Company did not incur any early termination obligations by
terminating its research. CTBCC and Globe also entered into a definitive
agreement which provided for Globe's assignment of a partial sublease in
respect of approximately 5400 square feet of laboratory space located at
the University of British Columbia to CTBCC.
In accordance with the terms of the agreement between the Company,
CTBCC and Globe, CTBCC has hired the majority of the former employees of
Globe.
"The purchase of Globe Laboratories Inc. assets and acquisition of key
staff will allow us to have direct control and management of the Company's
R & D activities", said Mr. Walter Korz, V.P., Drug Development at
Chemokine Therapeutics. "This will also help the Company to build on its
core competencies."
About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class of
signaling proteins which play a critical role in the growth,
differentiation, and maturation of cells necessary for fighting infection
as well as tissue repair and regeneration. Chemokines also have an
important role in cancer metastasis and growth. Chemokine Therapeutics is a
leader in research in the field of chemokines and has several products in
various stages of development.
Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: Statements in this document regarding managements'
future expectations, beliefs, goals, plans or prospects constitute
forward-looking statements that involve risks and uncertainties, which may
cause actual results to differ materially from the statements made. For
this purpose, any statements that are contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "projects",
and similar expressions are intended to identify forward-looking
statements. You are cautioned that such statements are subject to a
multitude of risks and uncertainties that could cause actual results,
future circumstances, or events to differ materially from those projected
in the forward-looking statements. These risks include, but are not limited
to, those associated with the success of research and development programs,
the regulatory approval process, competition, securing and maintaining
corporate alliances, market acceptance of the Company's products, the
availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company's
public disclosure documents and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the Company
disclaims any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise.
CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of
Public Relations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604)
822-0302, E-mail: devans@chemokine.net, Internet: www.chemokine.net
SOURCE Chemokine Therapeutics Corp.
IN today on record volume...something is up here! lets go to pennyland!
anyone have a clue why this is trading?? Someone going to do something with the shell???? P&D brewing???
Back to life? Just bought a few shares.
Company Web Site is Most Impressive.
http://www.chemokine.net/
Recent Press Releases Related to Breast Cancer
http://biz.yahoo.com/prnews/060221/to227.html?.v=20
http://biz.yahoo.com/prnews/060221/to227.html?.v=20
Recent Press Release Related to Prostate Cancer
http://biz.yahoo.com/prnews/060223/to296.html?.v=22
Recent Press Release Related to Brain Cancer
http://biz.yahoo.com/prnews/060216/to167.html?.v=21
Recent Press Release Regarding Lymphoma
Rhttp://biz.yahoo.com/prnews/060213/to044.html?.v=22ecent
Recent Press Release Regarding Regulatory Approval
for Test
http://biz.yahoo.com/prnews/060206/to187.html?.v=21
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
21
|
Created
|
02/26/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |